Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Atara Biotherapeutics

Blade Air Mobility

Fortress Biotech

FTC Solar

Gossamer Bio Inc

GrowGeneration Corp

iHeartMedia

Ondas Holdings

PureCycle Technologies

Ring Energy

Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.

11 Top Penny Stocks To Buy Now According To Insiders

Penny stocks, usually under $5 a share, draw traders looking for big gains. But these stocks can be risky.

Penny Stocks to Buy? 3 To Watch With Insider Trading In November

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman & Chief Executive Oﬃcer Steven Pieper - Chief Financial Oﬃcer John Shannon - Chief Operating Officer Conference Call Participants David Amsellem - Piper Sandler Juan Luis - Blaire Partners Operator Hello, everyone and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno.

Xeris Biopharma Holdings, Inc. (XERS) Q3 2023 Earnings Call Transcript

Xeris Biopharma Holdings (NASDAQ:XERS) revealed its latest quarterly results that highlighted strong revenue growth driven by its commercial products. “We continue to demonstrate record revenue growth as we execute on our strategy,” CEO Paul Edick said in a statement.

Xeris expects to hit the high end of revenue guidance after strong 3Q results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2023 and corporate highlights. “We continue to demonstrate record revenue growth as we execute on our strategy. Because of this strong performance, we are further tighten.

Xeris Biopharma Reports Third Quarter 2023 Financial Results

Xeris Biopharma Holdings (NASDAQ:XERS) revealed significant strides in its financial performance and collaboration agreements. The pharmaceutical company announced an upward revision of its full-year 2023 financial guidance from $145-$165 million to $155-$165 million.

Xeris Biopharma raises FY2023 guidance and receives milestone payment

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that, it is raising its full-year 2023 financial guidance and that it has received a $6 million milestone payment from Amgen, which acquired Horizon Therapeutics, for developing an ultra-concentrated, ready-to-use, subcutaneous injection of TEPEZ.

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

Xeris Biopharma Holdings (NASDAQ:XERS) told investors that it and its Xeris Pharmaceuticals Inc. subsidiary have entered into separate, privately negotiated exchange agreements with certain holders of Xeris' outstanding 5% convertible senior notes which mature in 2025.

Xeris Biopharma creates financial flexibility with private convertible note exchange transactions

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that on September 26, 2023, it and Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris (the “Guarantor”), entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of the Guaran.

Xeris Biopharma Announces Private Convertible Note Exchange Transactions

Xeris Biopharma Holdings Inc. is making strong progress on the top line and is on track to achieve a positive cash flow breakeven point in 2023. The company holds a substantial number of patents globally, contributing to its success in the pharmaceutical industry. Xeris Pharmaceuticals' notable product, Gvoke, has experienced significant market share expansion, providing reassurance for potential investors.

Xeris Biopharma Holdings: On Track To Be Cash Flow Positive

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on Thursday, September 28, 2023 at 3:00pm Eastern Time. A live webcast of the event will be avail.

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

Akebia Therapeutics

Esperion Therapeutics

If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage.

3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30am Eastern Time. A live webcast of the event will be available on the.

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Xeris Biopharma reports notable revenue growth in Q2 2023 for its main products, Gvoke, Keveyis, and Recorlev. The company's expenses have also increased, with a rise in the cost of goods sold and research and development expenses. Xeris has a satisfactory reserve for short-term needs but carries significant long-term debt, which may deter some investors.

Xeris Biopharma's Financial Pathway: Growth Amid Challenges

Xeris Biopharma has reported another quarter of record revenue driven by continued strong demand for the biopharmaceutical company's products Gvoke, Keveyis, and Recorlev. For the quarter which ended on June 30, 2023, the company achieved sales of $38 million, up 50% year-over-year and 14% sequentially.

Xeris Biopharma achieves record 2Q revenue and tightens full-year guidance

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman and Chief Executive Oﬃcer Steven Pieper - Chief Financial Oﬃcer Conference Call Participants Oren Livnat - H. C. Wainwright Glen Santangelo - Jefferies Operator Good morning all.

Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Earnings Call Transcript

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30, 2023 and corporate highlights. “We posted another record quarter of revenue due to the continued strong demand of all three products, as well as contributions from our partner.

Xeris Biopharma Reports Second Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, August 8, 2023. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss t.

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

Xeris Biopharma said it has shipped more than 1 million units of Gvoke, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children aged two years and older with diabetes. “We are proud to celebrate this major milestone of having shipped over 1 million units of Gvoke since its launch,” Xeris CEO Paul R.

Xeris Biopharma achieves shipping milestone for hypoglycemia treatment Gvoke

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Xeris has shipped more than one million units of Gvoke® – the company's ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. “We are proud to celebrate this majo.

Xeris Ships One Millionth Gvoke® Unit

Xeris Biopharma Holdings (NASDAQ:XERS) told investors that the first participant has been dosed in a multi-center, open-label, Phase 2 study of XP-8121 (levothyroxine sodium) for the treatment of adults with hypothyroidism. The biopharmaceutical company explained that the Phase 2 study (NCT05823012) is a non-randomized, open-label, single-arm, self-controlled study of XP-8121.

Xeris Biopharma says first participant dosed in Phase 2 clinical study of investigational subcutaneous levothyroxine in patients with hypothyroidism

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the first participant has been dosed in a multi-center, open label, Phase 2 study of XP-8121 for the treatment of adults with hypothyroidism. “Oral levothyroxine is one of the most prescribed medicines in the United States, generating more.

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment option. XERS has a range of successful products, such as Glucagon and Gvoke, and is aggressively securing patents to stay ahead of competition. XERS is expected to achieve profitability soon, with a breakeven cash flow by Q4 2023, and an estimated EPS of $0.23 by 2026.

Xeris Biopharma: Remarkable Market Share Expansion

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 10:30am Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' sect.

Xeris Biopharma to Participate at the Jefferies Healthcare Conference

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies Roanna Ruiz - SVB Securities Operator Hello all and warm welcome to the Xeris Biopharma Holding First Quarter 2023 Financial Results Call.

News for Xeris Biopharma Holdings Stock (XERS)